educatedsolutionsllc.com
New Haven Startup Tour
http://www.educatedsolutionsllc.com/nhstartup
The New Haven Startup Tour. Friday, Nov 14 12:00pm - 5:30pm. The New Haven Startup Tour. Provides the opportunity to look behind the scenes of New Haven area startups. You will get a chance to visit each company (usually in their offices) and meet the founders, talk to employees, and discover a whole world of opportunity most never knew existed in the New Haven area. Best of all it's FREE!
nlvpartners.com
New Leaf Venture Partners - Portfolio
http://www.nlvpartners.com/portfolio.html
With the success of our entrepreneurs our portfolio has. 20 billion-dollar companies, 34 acquired companies,. And 39 companies taken public, with more to come. Artificial intelligence platform that confirms medication adherence in clinical trials and high-risk patient populations. New York, NY. Platform for small-molecule drugs that induce targeted degradation of disease-causing intracellular proteins. New Haven, CT. NLV III / GROWTH. NLV III / GROWTH. NLV III / GROWTH. Berkeley Heights, NJ. New York, NY.
ocr.yale.edu
New Ventures | Office of Cooperative Research
http://ocr.yale.edu/new-ventures
Skip to main content. Office of Cooperative Research. Yale Device and Diagnostic Pipeline. Browse Faculty Research Interests. Patent Policy Acknowledgement and Agreement. Inventors' Distribution Agreement. Management of Equity in New Ventures. Committee on Cooperative Research. Consulting and the Patent Policy. Browse Faculty Research Interests. Patent Policy for Students. Support for Yale Student Innovators. Advanced Orthopedic Technologies is commercializing an innovative approach to repairing cartilag...
5amventures.com
5AM Ventures | Portfolio
http://5amventures.com/portfolio
THE 5AM PORTFOLIO: COMPANY PROFILES. Achaogen (AKAO) is a biopharmaceutical company developing small molecule therapeutics to treat infections caused by multi-drug resistant bacterial. IPO in March 2014. Alexza (ALXA) is a biopharmaceutical company developing drugs for local and systemic delivery through the lung. IPO in March 2006. Aprea is a biopharmaceutical company developing small molecule therapeutics for the treatment of cancer by reactivating mutant p53 tumor suppressor function. Calibrium is a b...
SOCIAL ENGAGEMENT